Division of Boston Scientific Corp.
Latest From Biocompatibles Inc.
UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.
The company pleaded guilty to a misdemeanor misbranding charge and agreed to pay $11m in criminal penalties and another $25m to resolve civil False Claims Act allegations. Biocompatibles reportedly marketed its LC Bead product as a drug-delivery product, even though it was cleared only for embolization.
BTG will pay $36m to the US Department of Justice to resolve claims its subsidiary, Biocompatibles, violated marketing regulations in promoting its LC Bead embolization system between 2003 and 2011.
August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
- Contact Info
Phone: (203) 262-4198
115 Hurley Rd.
Oxford, CT 06478
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.